Differences in CD4 count increases in veterans starting antiretroviral therapy with lopinavir/ritonavir or efavirenz
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Differences in CD4 count increases in veterans starting antiretroviral therapy with lopinavir/ritonavir or efavirenz ; volume:11 ; number:1 ; day:10 ; month:11 ; year:2008 ; pages:1-2 ; date:12.2008
Journal of the International AIDS Society / International AIDS Society ; 11, Heft 1 (10.11.2008), 1-2, 12.2008
- Creator
-
Bedimo, RJ
- Contributor
-
Drechsler, H.
Holodniy, M.
Pasley, M.
Woodward, W.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-11-S1-P9
- URN
-
urn:nbn:de:1111-2016052054024
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bedimo, RJ
- Drechsler, H.
- Holodniy, M.
- Pasley, M.
- Woodward, W.
- SpringerLink (Online service)
Other Objects (12)
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir
Lopinavir- und Efavirenz-Serumkonzentrationen bei antiretroviral behandelten HIV-infizierten Kindern in Südafrika
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Experience with ritonavir/atazanavir in HIV-positive antiretroviral-naïve individuals commencing therapy
O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients
Development of Efavirenz nanoparticle for enhanced efficiency of anti-retroviral therapy against HIV and AIDS
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir
Lopinavir- und Efavirenz-Serumkonzentrationen bei antiretroviral behandelten HIV-infizierten Kindern in Südafrika
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Experience with ritonavir/atazanavir in HIV-positive antiretroviral-naïve individuals commencing therapy
O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients
Development of Efavirenz nanoparticle for enhanced efficiency of anti-retroviral therapy against HIV and AIDS
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir
Lopinavir- und Efavirenz-Serumkonzentrationen bei antiretroviral behandelten HIV-infizierten Kindern in Südafrika
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Experience with ritonavir/atazanavir in HIV-positive antiretroviral-naïve individuals commencing therapy
O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients
Development of Efavirenz nanoparticle for enhanced efficiency of anti-retroviral therapy against HIV and AIDS
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study